Drug, across the briefings
Nazartinib across 12 cancers
Nazartinib appears in 12 of the briefings; no FDA label names any of them.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Anal cancer | phase 3 on EGFR | — | — | |
| Cervical cancer | phase 3 on EGFR | — | — | |
| Colorectal cancer | phase 3 on EGFR | 1 | 0 | |
| Cutaneous squamous cell carcinoma | phase 3 on EGFR | — | — | |
| Esophageal cancer | phase 3 on EGFR | 1 | 0 | |
| Gallbladder cancer | phase 3 on EGFR | — | — | |
| Glioblastoma | phase 3 on EGFR | — | — | |
| Head and neck cancer | phase 3 on EGFR | 1 | 0 | |
| Lung cancer | phase 3 on EGFR | 9 | 2 | |
| Nasopharyngeal carcinoma | phase 3 on EGFR | — | — | |
| Pancreatic cancer | phase 3 on EGFR | — | — | |
| Vulvar cancer | phase 3 on EGFR | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.